Fig. 2

Metabolic preferences vary between histologic subtypes. A. Heatmap showing relative metabolic pathways activities in the three histologic subgroups. B-D. Boxplots showing MTHFD2 and C15orf48 mRNA expression in the TCGA (B) and the EAS cohorts (C), and protein expression in the CPTAC cohort (D). Box centerlines, median; box limits, the 25th and 75th percentiles; box whiskers, 1.5 × the interquartile range. Comparisons were performed using two-sided Wilcoxon rank-sum test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n s not significant). E. Representative immunohistochemical images of MTHFD2 in lepidic, acinar and solid tumor regions. Scale bar, 50 μm. F. Violin plots showing the reactive oxygen species pathway score across the three histologic subgroups. Comparisons were performed by two-sided Wilcoxon rank-sum test. G. Kaplan–Meier survival curves showing the prognostic difference between the low and high C15orf48 expression groups in the TCGA LUAD cohort. H. Correlations between tumor metabolic pathway scores and the ratio of exhausted CD8 + T cells. P values were determined by Pearson's correlation test (*P < 0.1, **P < 0.05, ***P < 0.01)